- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02066675
Trabectedin First Line Therapy In Unfit Sarcoma Study (TR1US)
April 9, 2018 updated by: Italian Sarcoma Group
SAFETY AND ACTIVITY OF TRABECTEDIN AS FIRST LINE IN ADVANCED SOFT TISSUE SARCOMA (STS) PATIENTS UNFIT TO RECEIVE STANDARD CHEMOTHERAPY: A PROSPECTIVE PHASE II STUDY WITH CLINICAL AND MOLECULAR CORRELATES
Phase II, non-randomized, two-stage study according to Bryant & Day The study enroll patients with Metastatic and locally advanced soft tissue sarcoma unfit to receive standard chemotherapy (doxorubicin/epirubicin and/or ifosfamide)
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Soft tissue sarcomas are a group of rare and aggressive disease, comprising more than a hundred different histological subtypes and mainly originating from the embryonic mesoderm.
Today, they represent less than 1% of all adult cancers, with an incidence of 3/100000/year and a median age at diagnosis of 65 years.
Despite the progress done in the last decade, approximately 50% of STS patients still develop distant metastases within 3 years from the diagnosis and die from their disease.
Doxorubicin (or epirubicin) and ifosfamide have been proved to be active in the treatment of STS and they are widely used, alone or in combination, as a first line therapy for locally advanced and metastatic patients.
However, the response rate to the combination regimen in non-pretreated patients does not exceed 30-40%, and large randomized clinical trials failed to demonstrate any advantage in survival for the combination compared to single-agent treatment.
Trabectedin (Yondelis®) is a marine-derived anticancer agent that has been approved in the European Union as a single agent for the treatment of STS patients after failure of standard chemotherapy (doxorubicin and/or ifosfamide) or for those unsuited to receive these agents.
Even if the response rate in soft tissue sarcoma does not exceed 10%, trabectedin can provide a significant clinical benefit, by arresting disease progression in almost 50% of treated patients, with a progression-free survival rate of 20% at 6 months.
Trabectedin was found to be particularly active in the treatment of myxoid liposarcoma and uterine leiomyosarcoma, for which better results have been obtained in terms of response rate and survival, suggesting an histotype driven activity.
The toxicity profile of trabectedin given as second line therapy has been widely assessed in clinical studies and was largely manageable, with the majority of adverse events being grade 1 or 2 toxicities, generally reversible, dose or time dependent and noncumulative.
The good tolerability profile observed in the trials seems to be confirmed also in everyday clinical practice.
Conversely, few data are available at the moment about tolerability profile for those patients treated with trabectedin as first line because of medical conditions contraindicating the use of standard agents.
The aim of this phase II study is to assess and describe trabectedin toxicity profile in this subset of negatively selected advanced inoperable STS patients.
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Alessandria, Italy
- A.S.O. "SS Antonio e Biagio e Cesare Arrigo"
-
Bologna, Italy, 40136
- Istituti Ortopedici Rizzoli - Unit of chemotherapy of Muscoloskeletal Tumors
-
Frosinone, Italy
- Ospedale SS. Trinità di Sora
-
Genova, Italy
- IST
-
Napoli, Italy
- Policlinico Federico II Napoli
-
Padova, Italy
- Istituto Oncologico Veneto
-
Palermo, Italy
- Ospedale Giaccone
-
Roma, Italy
- Campus Biomedico
-
-
BG
-
Bergamo, BG, Italy
- Ospedali Riuniti di Bergamo
-
-
FC
-
Meldola, FC, Italy
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - IRST
-
-
GE
-
Genova, GE, Italy
- IRCCS Azienda Ospedaliera Universitaria San Martino IST
-
Genova, GE, Italy
- Ospedale Villa Scassi
-
-
Genovs
-
Genova, Genovs, Italy
- Ospedale Galliera
-
-
PO
-
Prato, PO, Italy
- Ospedale Misericordia e Dolce" Istituto Toscano Tumori, Azienda USL4
-
-
TO
-
Torino, TO, Italy, 10153
- Presidio Sanitario Gradenigo
-
-
Torino
-
Candiolo, Torino, Italy, 10060
- I.R.C.C. - Unit of Medical Oncology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion criteria
- Adult patients (≥18 years), who, in the judgment of the clinician, is deemed not suitable to receive an anthracycline and/or ifosfamide based chemotherapy;
- Pathological diagnosis of soft tissue sarcoma
- Inoperable, locally advanced or metastatic tumor;
- Unsuited to receive doxorubicine and ifosfamide: ie stable arrhythmia, previous myocardial infarction; age≥80 years
- Eastern Cooperative Oncology Group Performance Status 0-2
- Glomerular filtration rate ≥30 mL per min
- Adequate hematologic function: Hemoglobin ≥9 g/dL; Absolute neutrophil count ≥1,500/μL, and Platelet count ≥100,000/microliter
- Creatinine phosphokinase < 2.5 Upper Normal Limit
- Adequate hepatic function: total bilirubin < Upper Normal Limit, total alkaline phosphatase < 2.5 Upper Normal Limit, or if > 2.5 Upper Normal Limit consider alkaline phosphatase liver fraction or gamma-glutamyltransferase or 5' nucleotidase must be < Transminase <2.5 x Upper Normal Limit, Albumin > 20 g/L.
- Patient´s written informed consent
Exclusion criteria
- Prior exposure to Trabectedin
- Performance status ≥2.
- Prior treatment with anthracyclines and or ifosfamide.
- History of other malignancies (except basal cell carcinoma or cervical carcinoma in situ, adequately treated), unless in remission for 5 or more years and judged of negligible potential of relapse.
- Active viral hepatitis or chronic liver diseases, which in the judgement of the primary investigator represents a clinical contraindication to the therapy.
- Unstable cardiac condition, including congestive heart failure or angina pectoris, myocardial infarction within 6 months before enrolment, uncontrolled arterial hypertension or arrhythmias, left ventricular ejection fraction <40%
- Active major infection.
- Other serious concomitant illnesses
- Pregnant subjects or breast feeding, or planning to become pregnant within 6 months after the end of treatment All sexually active female patients with reproductive potential must have a negative pregnancy test (serum or urine) within the 7 days prior to enrollment and must agree to use highly effective contraception during treatment and for 6 months after the end of treatment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Trabectedin
Trabectedin administered at the dose of 1.5 mg/mq-1.3
mg/mq a 24-hour continuous infusion via a central venous access, every 3 weeks
|
Each patients will receive intravenous trabectedin (1.5 mg/mq-1.3
mg/mq) over 24 hours every 3 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression Free Survival Rate
Time Frame: 3 Months
|
The primary end point of this trial is the Progression Free Survival Rate at 3 months Non progression, is defined as Complete Response, Partial Response or Stable Disease according to Response Evaluation Criteria In Solid Tumours v.1.1 criteria.
|
3 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tolerability and intolerable adverse reaction rate.
Time Frame: Day21
|
Intolerable toxicity is defined as every Adverse Events leading to treatment discontinuation or dose-reduction; furthermore, any Adverse Events of at least grade 3 not resolved within 3 weeks of appropriate management should be regarded as an intolerable toxicity event.
For haematological toxicity, given that the use of growth factors will be allowed, an intolerable toxicity is defined either as any grade 4 event, or a grade 3 event not resolved with adequate treatment.
|
Day21
|
Objective response rate
Time Frame: 5 years
|
Proportion of patients whose best response is either partial response or complete response
|
5 years
|
Progression free survival
Time Frame: Average of 5 Months
|
It's the length of time during and after the treatment of a disease, that a patient lives with the disease but it does not progress
|
Average of 5 Months
|
Overall survival
Time Frame: 18 Months (average)
|
it's the length of time after the treatment's end that the patient survives
|
18 Months (average)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Federica Grosso, MD, ASO SS Antonio e Biagio e C Arrigo Alessandria, Italy
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2014
Primary Completion (Actual)
December 31, 2016
Study Completion (Actual)
December 31, 2016
Study Registration Dates
First Submitted
February 13, 2014
First Submitted That Met QC Criteria
February 17, 2014
First Posted (Estimate)
February 19, 2014
Study Record Updates
Last Update Posted (Actual)
April 11, 2018
Last Update Submitted That Met QC Criteria
April 9, 2018
Last Verified
April 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ISG TR1US
- 2013-001467-23 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic and Locally Advanced Soft Tissue Tumor Patients Unfit to Receive
-
OHSU Knight Cancer InstituteNovartis Pharmaceuticals; Oregon Health and Science UniversityCompletedStage III Soft Tissue Sarcoma AJCC v7 | Stage IV Soft Tissue Sarcoma AJCC v7 | Locally Advanced Leiomyosarcoma | Unresectable Leiomyosarcoma | Myxofibrosarcoma | Metastatic Malignant Peripheral Nerve Sheath Tumor | Metastatic Synovial Sarcoma | Metastatic Undifferentiated Pleomorphic Sarcoma | Unresectable... and other conditionsUnited States
-
University of WashingtonAadi Bioscience, Inc.Active, not recruitingAdvanced Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Locally Advanced Soft Tissue SarcomaUnited States
-
National Cancer Institute (NCI)SuspendedLocally Advanced Leiomyosarcoma | Metastatic Undifferentiated Pleomorphic Sarcoma | Locally Advanced Liposarcoma | Locally Advanced Undifferentiated Pleomorphic Sarcoma | Locally Advanced Extraskeletal Myxoid Chondrosarcoma | Locally Advanced Unresectable Soft Tissue SarcomaUnited States, Canada
-
National Cancer Institute (NCI)CompletedStage III Soft Tissue Sarcoma AJCC v7 | Stage IV Soft Tissue Sarcoma AJCC v7 | Pleomorphic Liposarcoma | Metastatic Undifferentiated Pleomorphic Sarcoma | Metastatic Unresectable Sarcoma | Unresectable Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Locally Advanced Soft Tissue Sarcoma | Metastatic... and other conditionsUnited States
-
Centre Oscar LambretCanceropôle Nord OuestNot yet recruitingSarcoma Metastatic | Locally Advanced Soft Tissue SarcomaFrance
-
ImmunityBio, Inc.CompletedMetastatic, Locally Advanced, or Unresectable Soft Tissue SarcomaUnited States
-
CytRxUnknownUnresectable Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Locally Advanced Soft Tissue SarcomaUnited States, Australia, Russian Federation, Hungary, India, Romania, Ukraine
-
ImmunityBio, Inc.CompletedMetastatic, Locally Advanced or Unresectable Soft Tissue SarcomaUnited States, Spain, Denmark, Israel, Canada, Australia, Hungary, Chile, France, Italy, Netherlands, Poland, Russian Federation
-
Ankyra Therapeutics, IncRecruitingSolid Tumor | Advanced Solid Tumor | Metastatic Solid Tumor | Malignant Solid Tumor | Cutaneous Tumor | Subcutaneous Tumor | Metastasis to Soft TissueUnited States
-
Institut BergoniéMinistry of Health, France; PharmaMarTerminatedAdult Patients With Unresectable Locally Advanced or Metastatic, Relapsed/Refractory Dedifferentiated LiposarcomaFrance
Clinical Trials on Trabectedin
-
Italian Sarcoma GroupAstraZeneca; PharmaMarActive, not recruitingAdvanced Soft Tissue SarcomaItaly
-
Italian Sarcoma GroupPharmaMarWithdrawnLeiomyosarcoma | Liposarcoma | Synovial SarcomaItaly
-
PharmaMar, SpainCompletedSoft Tissue SarcomaGermany
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)Completed
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedSarcomaUnited States
-
University of Colorado, DenverWithdrawn
-
Grupo Español de Investigación en Cáncer de OvarioCompleted
-
European Organisation for Research and Treatment...CompletedSarcoma | Small Intestine Cancer | Ovarian Cancer | Brain and Central Nervous System Tumors | Endometrial Cancer | Gastrointestinal Stromal Tumor
-
European Organisation for Research and Treatment...CompletedUnspecified Adult Solid Tumor, Protocol SpecificFrance, Spain, Denmark, Netherlands, Norway, Belgium, United Kingdom, Israel, Italy, Switzerland, Germany, Austria, Greece, Portugal
-
PharmaMarCompletedRelapsed Ovarian CancerSpain, France, Italy, Belgium, Germany